Phaseline

Companies › Prevail Therapeutics

Prevail Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Neurology, Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LY3884961
Recombinant adeno-associated virus (AAV) vector delivering GBA gene
GBAPhase 1Gaucher Disease, Type 2; Gaucher Disease; Parkinson DiseaseFeb 2027
LY3884963
Gene therapy delivering PGRN (progranulin) to increase progranulin protein levels
GRNPhase 1Frontotemporal DementiaNov 2029
LY3962681–Phase 1Parkinson's DiseaseJul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04411654LY3884961Phase 1Gaucher Disease, Type 2Metabolic and endocrineFeb 2027
NCT04408625LY3884963Phase 1Frontotemporal DementiaNeurologyNov 2029
NCT06565195LY3962681Phase 1Parkinson's DiseaseNeurologyJul 2030
NCT05487599LY3884961Phase 1Gaucher DiseaseMetabolic and endocrineAug 2031
NCT04127578LY3884961Phase 1Parkinson DiseaseNeurologyAug 2031

Targets

GBA (1) GRN (1)

Companies with the same targets

Lingyi Biotech Spur Therapeutics Azafaros Bial R&D Investments AviadoBio Voyager Therapeutics Passage Bio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.